Last reviewed · How we verify
Captopril,Hydrochlorothiazide
Captopril,Hydrochlorothiazide is a ACE inhibitor + thiazide diuretic combination Small molecule drug developed by West China Hospital. It is currently FDA-approved for Hypertension, Heart failure.
This combination reduces blood pressure by inhibiting angiotensin-converting enzyme (ACE) to dilate blood vessels and promoting sodium and water excretion through diuretic action.
Captopril, a type of ACE inhibitor, is used to treat hypertension and has been studied in the context of COVID-19 severity and mortality. It is often combined with Hydrochlorothiazide, a diuretic, to manage blood pressure.
At a glance
| Generic name | Captopril,Hydrochlorothiazide |
|---|---|
| Sponsor | West China Hospital |
| Drug class | ACE inhibitor + thiazide diuretic combination |
| Target | ACE (angiotensin-converting enzyme); sodium-chloride cotransporter in distal convoluted tubule |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Captopril blocks ACE, preventing conversion of angiotensin I to angiotensin II, which reduces vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that increases urinary sodium and water excretion, lowering blood volume and pressure. Together, they provide complementary antihypertensive effects.
Approved indications
- Hypertension
- Heart failure
Common side effects
- Cough
- Dizziness
- Hyperkalemia
- Hypokalemia
- Hypotension
- Angioedema
- Rash
Key clinical trials
- Peripheral Vascular Effects of Sulfhydryl-containing Antihypertensive Pharmacotherapy on Microvessels in Humans (PHASE1, PHASE2)
- A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions (PHASE1)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Coronavirus (COVID-19) ACEi/ARB Investigation (PHASE4)
- The Standardized Management of Hypertension in Rural Shaanxi (NA)
- Matão Controlling Hypertension (MatCH Study): Rationale and Design (EARLY_PHASE1)
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
- Treatment of Hypertension in Tibetan Adult Population (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Captopril,Hydrochlorothiazide CI brief — competitive landscape report
- Captopril,Hydrochlorothiazide updates RSS · CI watch RSS
- West China Hospital portfolio CI
Frequently asked questions about Captopril,Hydrochlorothiazide
What is Captopril,Hydrochlorothiazide?
How does Captopril,Hydrochlorothiazide work?
What is Captopril,Hydrochlorothiazide used for?
Who makes Captopril,Hydrochlorothiazide?
What drug class is Captopril,Hydrochlorothiazide in?
What development phase is Captopril,Hydrochlorothiazide in?
What are the side effects of Captopril,Hydrochlorothiazide?
What does Captopril,Hydrochlorothiazide target?
Related
- Drug class: All ACE inhibitor + thiazide diuretic combination drugs
- Target: All drugs targeting ACE (angiotensin-converting enzyme); sodium-chloride cotransporter in distal convoluted tubule
- Manufacturer: West China Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Heart failure
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing